litlas
Log inCreate account

Steven D. Nathan

Active 1993–2026

160
Papers
21,051
Citations
74
h-index
145
i10-index

Citations

Citations per year for Steven D. Nathan1995: 4 citations1996: 2 citations1997: 3 citations1998: 4 citations1999: 2 citations2000: 1 citations2002: 3 citations2003: 5 citations2004: 3 citations2005: 11 citations2006: 21 citations2007: 39 citations2008: 72 citations2009: 59 citations2010: 58 citations2011: 57 citations2012: 79 citations2013: 92 citations2014: 131 citations2015: 167 citations2016: 165 citations2017: 234 citations2018: 205 citations2019: 689 citations2020: 755 citations2021: 766 citations2022: 825 citations2023: 687 citations2024: 1,171 citations2025: 368 citations2026: 24 citations2001: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,845 citing papers, 25.1% of this breakdownChina: 629 citing papers, 8.6% of this breakdownUnited Kingdom: 619 citing papers, 8.4% of this breakdownGermany: 471 citing papers, 6.4% of this breakdownItaly: 395 citing papers, 5.4% of this breakdownFrance: 342 citing papers, 4.7% of this breakdownCanada: 332 citing papers, 4.5% of this breakdownAustralia: 282 citing papers, 3.8% of this breakdownJapan: 268 citing papers, 3.7% of this breakdownSpain: 225 citing papers, 3.1% of this breakdownNetherlands: 196 citing papers, 2.7% of this breakdownSwitzerland: 154 citing papers, 2.1% of this breakdown
0%25.1%Other 21.5%

Institutions

Fields

  • Medicine90.5%
  • Biochemistry, Genetics and Molecular Biology6.6%
  • Immunology and Microbiology1.1%
  • Engineering0.4%
  • Computer Science0.3%
  • Health Professions0.3%
  • Other0.8%

Topics

  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis20.4%
  • Pulmonary Hypertension Research and Treatments7.7%
  • Chronic Obstructive Pulmonary Disease (COPD) Research5.6%
  • Systemic Sclerosis and Related Diseases4%
  • Sarcoidosis and Beryllium Toxicity Research4%
  • Transplantation: Methods and Outcomes3.1%
  • Other55.2%

Coauthors

All papers

Open in search
  1. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

    Authors: Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, Eduard Gorina, Peter Hopkins, David Kardatzke, Lisa Lancaster, David J. Lederer, Steven D. Nathan, Carlos A. Pereira, Steven A. Sahn, Robert Sussman, Jeffrey J. Swigris, Paul W. Noble - New England Journal of Medicine 2014 cited by 3,949

  2. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

    Authors: Aaron B. Waxman, Ricardo Restrepo‐Jaramillo, Thenappan Thenappan, Ashwin Ravichandran, Peter A. Engel, Abubakr Bajwa, Roblee P. Allen, Jeremy Feldman, Rahul Argula, Peter Smith, Kristan Rollins, C. Q. Deng, Leigh Peterson, Heidi Bell, Victor F. Tapson, Steven D. Nathan - New England Journal of Medicine 2021 cited by 614

  3. Pulmonary hypertension in chronic lung disease and hypoxia

    Authors: Steven D. Nathan, Joan Albert Barberà, Seán Gaine, Sergio Harari, Fernando J. Martínez, Horst Olschewski, Karen M. Olsson, Andrew J. Peacock, Joanna Pepke‐Żaba, Steeve Provencher, Norbert Weißmann, Werner Seeger - European Respiratory Journal 2018 cited by 761

  4. Lactic Acid Is Elevated in Idiopathic Pulmonary Fibrosis and Induces Myofibroblast Differentiation via pH-Dependent Activation of Transforming Growth Factor-β

    Authors: R.M. Kottmann, Ajit A. Kulkarni, Katie Smolnycki, Elizabeth Lyda, Thinesh Dahanayake, Rami Salibi, Sylvie Honnons, Carolyn Jones, Nancy Isern, Jian Zhi Hu, Steven D. Nathan, Geraldine M. Grant, Richard P. Phipps, Patricia J. Sime - American Journal of Respiratory and Critical Care Medicine 2012 cited by 408

  5. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

    Authors: Lisa Lancaster, João A. de Andrade, Joseph D. Zibrak, María L. Padilla, Carlo Albera, Steven D. Nathan, Marlies Wijsenbeek, John L. Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel - European Respiratory Review 2017 cited by 288

  6. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

    Authors: Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre, Talmadge E. King - European Respiratory Journal 2015 cited by 463

  7. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

    Authors: Christopher J. Rhodes, Ken Batai, Marta Bleda, Matthias Haimel, Laura Southgate, Marine Germain, Michael W. Pauciulo, Charaka Hadinnapola, Jurjan Aman, Barbara Girerd, Amit Arora, Jo Knight, Ken B. Hanscombe, Jason H. Karnes, Marika Kaakinen, Henning Gall, Anna Ulrich, Lars Harbaum, Inês Cebola, Jorge Ferrer, Katie A. Lutz, Emilia M. Swietlik, Ferhaan Ahmad, Philippe Amouyel, Stephen L. Archer, Rahul Argula, Eric D. Austin, David B. Badesch, Sahil Bakshi, Christopher F. Barnett, Raymond L. Benza, Nitin Bhatt, Harm Jan Bogaard, Charles D. Burger, Murali M. Chakinala, Colin Church, Gerry Coghlan, Robin Condliffe, Paul A. Corris, Cesare Danesino, Stéphanie Debette, C. Gregory Elliott, Jean Elwing, Mélanie Eyries, Terry Fortin, André Franke, Robert P. Frantz, Adaani Frost, Joe G. N. Garcia, Stefano Ghio, Hossein-Ardeschir Ghofrani, J. Simon R. Gibbs, John B. Harley, Hua He, Nicholas S. Hill, Russel Hirsch, Arjan C. Houweling, Luke Howard, D. Dunbar Ivy, David G. Kiely, James R. Klinger, Gábor Kovács, Tim Lahm, Matthias Laudes, Rajiv D. Machado, Robert V. MacKenzie Ross, Keith Marsolo, Lisa J. Martin, Shahin Moledina, David Montani, Steven D. Nathan, Michael Newnham, Andrea Olschewski, Horst Olschewski, Ronald J. Oudiz, Willem H. Ouwehand, Andrew J. Peacock, Joanna Pepke‐Żaba, Zia Ur Rehman, Ivan M. Robbins, Dan M. Roden, Erika B. Rosenzweig, Ghulam Saydain, Laura Scelsi, Robert Schilz, Werner Seeger, Christian M. Shaffer, Robert W. Simms, Marc A. Simon, Olivier Sitbon, Jay Suntharalingam, Haiyang Tang, Alexander Tchourbanov, Thenappan Thenappan, Fernando Torres, Mark Toshner, Carmen Treacy, Anton Vonk Noordegraaf, Quinten Waisfisz, Anna K. Walsworth and 18 more - The Lancet Respiratory Medicine 2018 cited by 213

  8. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

    Authors: Steven D. Nathan, Jürgen Behr, Harold R. Collard, Vincent Cottin, Marius M. Hoeper, Fernando J. Martínez, Tamera J. Corte, Anne Keogh, Hanno Leuchte, Nesrin Moğulkoç, Silvia Ulrich, Wim Wuyts, Zhen Yao, Francis Boateng, Athol U. Wells - The Lancet Respiratory Medicine 2019 cited by 241

  9. Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis

    Authors: Christopher J. Lettieri, Steven D. Nathan, Scott D. Barnett, Shahzad Ahmad, Andrew F. Shorr - CHEST Journal 2006 cited by 871

  10. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

    Authors: Ganesh Raghu, Juergen Behr, Kevin M. Brown, Jim Egan, Steven M. Kawut, Kevin R. Flaherty, Fernando J. Martínez, Steven D. Nathan, Athol U. Wells, Harold R. Collard, Ulrich Costabel, Luca Richeldi, João A. de Andrade, Nasreen Khalil, Lake Morrison, David J. Lederer, Lixin Shao, Xiaoming Li, Patty Pedersen, A. Bruce Montgomery, Jason W. Chien, Thomas G. O’Riordan, the ARTEMIS-IPF Investigators* - Annals of Internal Medicine 2013 cited by 543

  11. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

    Authors: Jürgen Behr, Steven D. Nathan, Wim Wuyts, Nesrin Mogulkoc Bishop, Demosthenes Bouros, Κατερίνα Αντωνίου, Julien Guiot, Mordechai R. Kramer, Klaus-Uwe Kirchgaessler, Monica Bengus, Frank Gilberg, Andras Perjesi, Sergio Harari, Athol U. Wells - The Lancet Respiratory Medicine 2020 cited by 134

  12. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management

    Authors: Karen M. Olsson, Tamera J. Corte, Jan C. Kamp, David Montani, Steven D. Nathan, Lavinia Neubert, Laura Price, David G. Kiely - The Lancet Respiratory Medicine 2023 cited by 119

  13. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

    Authors: Steven D. Nathan, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K. Glassberg, David Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa Lancaster, David J. Lederer, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre, Paul W. Noble - The Lancet Respiratory Medicine 2016 cited by 332

  14. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

    Authors: Steven D. Nathan, Aaron B. Waxman, Sudarshan Rajagopal, Amy Hajari Case, Shilpa Johri, Hilary M. DuBrock, David J. De La Zerda, Sandeep Sahay, Christopher S. King, Lana Melendres‐Groves, Peter Smith, Eric Shen, Lisa Edwards, Andrew C. Nelsen, Victor F. Tapson - The Lancet Respiratory Medicine 2021 cited by 141

  15. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation

    Authors: Sean Agbor-Enoh, Yan Wang, Ilker Tunc, Moon Kyoo Jang, Andrew A. Davis, Iwijn De Vlaminck, Helen Luikart, Pali D. Shah, I. Timofte, Anne Brown, A. Marishta, K. Bhatti, S. Gorham, U. Fideli, Jennifer Wylie, David R. Grimm, Natalie Goodwin, Yanqin Yang, K. Patel, Jun Zhu, Aldo Iacono, Jonathan B. Orens, Steven D. Nathan, Charles C. Marboe, Gerald J. Berry, Stephen R. Quake, Kiran K. Khush, Hannah A. Valantine - EBioMedicine 2019 cited by 150

  16. Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study

    Authors: Moon Kyoo Jang, Ilker Tunc, Gerald J. Berry, Charles C. Marboe, Hyesik Kong, Michael B. Keller, Pali D. Shah, I. Timofte, Anne Brown, Ileana L. Ponor, Cedric Mutebi, Mary Carmelle Philogene, Kai Yu, Aldo Iacono, Jonathan B. Orens, Steven D. Nathan, Sean Agbor-Enoh - The Journal of Heart and Lung Transplantation 2021 cited by 92

  17. Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury

    Authors: T. Andargie, Takayuki Tsuji, Fayaz Seifuddin, Moon Kyoo Jang, Peter S.T. Yuen, Hyesik Kong, Ilker Tunc, Komudi Singh, Ananth Charya, Kenneth J. Wilkins, Steven D. Nathan, Andrea L. Cox, Mehdi Pirooznia, Robert A. Star, Sean Agbor-Enoh - JCI Insight 2021 cited by 153

  18. Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

    Authors: Anna L. Peljto, Rachel Z. Blumhagen, Avram Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben Moodley, Martina Vašáková, Elisabeth Bendstrup, Jesper Rømhild Davidsen, Raphaël Borie, Bruno Crestani, Philippe Dieudé, Francesco Bonella, Ulrich Costabel, Gunnar Guðmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife McElroy, Joshua A. Olaniyi, Katherine Ma O’Reilly, Luca Richeldi, Paolo Maria Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Köktürk, Nesrin Moğulkoç, Christine Fiddler, Nikhil Hirani, Gísli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena Foster, Kevin F. Gibson, Marilyn K. Glassberg, Daniel J. Kass, Jonathan A. Kropski, David J. Lederer, A. Linderholm, Jim Loyd, Susan Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy Palmisciano, Cristina Reichner, Mauricio Rojas, Jesse Roman, Neil W. Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. Prêle, Juan Ignacio Enghelmayer, María Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Šterclová, Tewodros Haile Gebremariam, Marjukka Myllärniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moisés Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, María Molina‐Molina, Lurdes Planas‐Cerezales, Gunilla Westergren‐Thorsson, Albert V. Smith, Ani Manichaikul, John S. Kim and 15 more - American Journal of Respiratory and Critical Care Medicine 2023 cited by 80

  19. Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium

    Authors: Steven D. Nathan, Oksana A. Shlobin, Nargues Weir, Shahzad Ahmad, Julienne M. Kaldjob, Edwinia Battle, Michael J. Sheridan, Roland M. du Bois - CHEST Journal 2011 cited by 365

  20. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

    Authors: Aaron B. Waxman, Ricardo Restrepo‐Jaramillo, Thenappan Thenappan, Peter A. Engel, ABUBAKR A BAJWA, Ashwin Ravichandran, Jeremy Feldman, Amy Hajari Case, Rahul Argula, Victor F. Tapson, Peter Smith, C. Q. Deng, Eric Shen, Steven D. Nathan - European Respiratory Journal 2023 cited by 65

  21. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis

    Authors: Steven D. Nathan, Jürgen Behr, Vincent Cottin, Lisa Lancaster, Peter Smith, CQ Deng, Natalie Breytenbach, Heidi Bell, Leigh Peterson, Kevin R. Flaherty - BMJ Open Respiratory Research 2022 cited by 67

  22. The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

    Authors: Martin Kolb, Stylianos E. Orfanos, Christopher Lambers, Kevin R. Flaherty, Alison Masters, Lisa Lancaster, Adam M. Silverstein, Steven D. Nathan - Advances in Therapy 2022 cited by 44

  23. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

    Authors: Sylvia Nikkho, Manuel J. Richter, Eric Shen, Steven H. Abman, Katerina Antoniou, Jonathan H. Chung, Peter Fernandes, Paul M. Hassoun, Howard M. Lazarus, Horst Olschewski, Lucilla Piccari, Mitchell A. Psotka, Rajan Saggar, Oksana A. Shlobin, Norman Stockbridge, Patrizio Vitulo, Carmine Dario Vizza, Stephen J. Wort, Steven D. Nathan - Pulmonary Circulation 2022 cited by 61

  24. A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis

    Authors: Steven D. Nathan, Kevin R. Flaherty, Marilyn K. Glassberg, Ganesh Raghu, Jeffrey J. Swigris, Roger A. Alvarez, Neil Ettinger, Jim Loyd, Peter Fernandes, Hunter Gillies, Bo Kim, Parag S. Shah, Lisa Lancaster - CHEST Journal 2020 cited by 106